SCHEMBL3613875

SCHEMBL3613875

CC(C)(C)OC(=O)C1CNCC2C(=O)N(c3cccc(C(F)(F)F)c3)CN12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
HSD17B10 Q99714 2/20 0.39
HSP90AA1 P07900 1/20 0.39
ALOX15 P16050 1/20 0.39
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
HTR2B P41595 1/20 0.38
GAA P10253 1/20 0.38
TSHR P16473 2/20 0.37
GLA P06280 1/20 0.37
CYP1A2 P05177 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
PPARG P37231 1/20 0.36
PPARD Q03181 1/20 0.36
PPARA Q07869 1/20 0.36
PRKCZ Q05513 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MAPK1 P28482 1/20 0.36
OPRM1 P35372 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3606120 0.89 POLB (0.37) ALDH1A1HTR2AHTR2CHTR2BPRKCZ
SCHEMBL3605596 0.88 ALDH1A1 (0.37) ALDH1A1HTR2AHTR2CHTR2BMEN1
SCHEMBL3606731 0.87 OPRM1 (0.38) ALDH1A1MEN1KMT2APRKCZOPRM1
SCHEMBL3601055 0.87 GPR119 (0.41) ALDH1A1HSD17B10GAATSHRKMT2A
SCHEMBL3597127 0.87 DDB1 (0.34)
SCHEMBL3609983 0.86 ALDH1A1 (0.36) ALDH1A1MEN1KMT2AALKBH5
SCHEMBL3601852 0.86 MAPT (0.40) ALDH1A1HSD17B10GAAKMT2ASMN1; SMN2
SCHEMBL3601271 0.86 HDAC1 (0.32)
SCHEMBL3604816 0.85 GPR119 (0.36) KDM4E
SCHEMBL3607457 0.85 USP30 (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004249-A1 Bicyclic heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-07 US disclosed
EP-2039695-A1 BICYCLIC HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2009-03-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004249-A1 Bicyclic heterocyclic compound and use thereof HTR2C, HTR5A, HTR2A ALDH1A1 1162/4885HSD17B10 1707/4885HSP90AA1 3684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.